Dapagliflozin in Patients with Chronic Kidney Disease.
378
mentions
- X 271
- News 68
- Facebook 17
- Blogs 9
- +3 more
Hiddo J L Heerspink
PubHawk tracks social media discussions for 6 articles by authors named Hiddo J L Heerspink.
Mentions
1,476
Peak: 114 in Aug 2025
across 6 tracked articles
Extended reach
6,052,244
potential audience
Total likes
6,526
Video views
392,849
Mentions per month
Apr 2019 – Nov 2025Where it's discussed
-
X / Twitter1,105 posts
-
News247 articles
-
Facebook54 posts
-
Blogs34 articles
-
YouTube20 videos
-
Bluesky14 posts
-
Reddit2 posts
Tracked by PubHawk
Most discussed articles
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
337
mentions
- X 216
- News 72
- Facebook 27
- Blogs 17
- +2 more
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
307
mentions
- X 204
- News 86
- Bluesky 10
- Blogs 5
- +1 more
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
224
mentions
- X 200
- News 15
- Facebook 4
- Blogs 3
- +1 more
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
115
mentions
- X 107
- Facebook 3
- News 3
- YouTube 2
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.
115
mentions
- X 107
- Facebook 3
- News 3
- YouTube 2
From PubMed
All publications
Searching PubMed…